Ranjit Bindra

Ranjit Bindra has an extensive work experience in the field of medicine and academia. Ranjit is currently working at Yale University School of Medicine as the Harvey and Kate Cushing Professor and Vice Chair for Translational Research. Prior to this, they held positions as a Professor, Associate Professor, and Assistant Professor in the Department of Therapeutic Radiology.

In addition to their academic roles, Bindra is also involved in various entrepreneurial ventures. Ranjit is a co-founder of Modifi Bio, B3 Therapeutics, Alphina Therapeutics, and Cybrexa Therapeutics, which are all biotech companies focused on developing innovative therapies.

Before joining Yale University, Bindra served as a Physician-Scientist in Radiation Oncology at MSKCC, where they conducted research on the cellular response to ionizing radiation and developed therapies for malignant brain tumors.

Early in their career, Bindra co-founded Helix Therapeutics, LLC, a company that developed oligonucleotide-based therapies to correct gene mutations in blood stem cells for genetic diseases.

Their educational background includes being an MD/PhD student at Yale University School of Medicine. Overall, Bindra has a diverse and accomplished work history in both academia and entrepreneurship within the medical field.

Ranjit Bindra completed their education with a Bachelor of Science (BS) degree in Molecular Biophysics and Biochemistry from Yale University between 1994 and 1998. Ranjit then pursued further education at Yale University School of Medicine from 2000 to 2007, where they obtained a joint MD/PhD degree. Their specific area of study during their doctoral program was Cancer Biology.